Controlled medicines belong to a number of therapeutic classes. The World Health Organization (WHO) has produced a Model List of Essential Medicines and a Model List of Essential Medicines for Children. Among the controlled medicines on these lists are: opioid analgesics; long-acting opioids for the treatment of opioid dependence; medicines for emergency obstetrics; benzodiazepines both for mental disorders and against epilepsy; and phenobarbital, also an anti-epileptic. Ketamine is listed as an anaesthetic and, although not controlled under the international treaties, many countries now control it under their national responsibility. Ketamine is often the only possibility for anaesthesia in resource-poor, often rural settings in low- and middle-income countries. Various other medicines not listed on the WHO Model Lists of Essential Medicines are controlled, including stimulants for the treatment of attention-deficit hyperactivity disorder (ADHD) and similar syndromes.

For classes other than opioid analgesics, we have limited data on their availability. However, it is certain that many do not have access to opioids for the treatment of opioid dependence. Furthermore, it has been reported that in low- and middle-income countries many patients with epilepsy are not treated and are thus needlessly disabled. In Africa, 80% of the population affected by epilepsy have no access to essential anti-epileptic medicines (World Health Organization, [@r9]). With benzodiazepines we estimate that under- and over-treatment occur simultaneously, but whether over- or under-treatment dominates depends very much on the country situation.

During the past century the world has developed an international system of drugs control that has gradually become more stringent. The current treaties date back to 1961 (amended by a protocol in 1972) and 1971. After stating that the parties are 'concerned with the health and welfare of mankind', the treaties define the objectives of the prevention of 'abuse' and dependence, and of keeping the controlled medicines available for medical and scientific purposes. However, the focus over time has been on the prevention of misuse and dependence, so much so that the accessibility and availability of the medicines containing the substances have declined.

Legislation in many countries does not allow for the medical use of these medicines; even where it is allowed, procedures are complex and in practice patients often do not have access. Also, many physicians do not have adequate knowledge of how to use these substances and many are biased against their use because they believe patients will become very easily dependent on these medicines when prescribed, or even will be killed by their medicines. Patients and their families often hold similar attitudes and hence many refuse potentially beneficial treatments. Moreover, procurement can be difficult because of the bureaucracy involved and low turn-over expectations may hamper enterprises seeking market access for these medicines.

WHO action towards better patient access {#s1}
========================================

Since 1986, the International Narcotics Control Board (INCB) has requested that countries improve access to controlled medicines. For instance, in its 2009 annual report, it once again declared that:

> One of the fundamental objectives of the international drug control treaties is to ensure the availability of narcotic drugs and psychotropic substances for medical and scientific purposes and to promote access to and rational use of narcotic drugs and psychotropic substances. (United Nations, [@r7])

Over the last few years, attention to the problem of low accessibility has increased, as shown by resolutions adopted by the World Health Assembly (World Health Organization, [@r8]), the United Nations Economic and Social Council (United Nations, [@r6]) and the Commission on Narcotic Drugs ([@r1]). As a result of the former two resolutions, the INCB and WHO developed the Access to Controlled Medications Programme in 2007, operated by the WHO. Many other organisations have developed activities to improve access to these medicines. Human Rights Watch ([@r2]) and the Open Society Institute ([@r4]) have published on the topic.

The WHO's *Ensuring Balance in National Policies on Controlled Substances* provides guidance on how to develop policy and legislation that will improve access to these medicines (World Health Organization, [@r8]). It includes 21 guidelines based on the principle of balance, i.e. that policies should aim to optimise public health outcomes by maximising access to controlled medicines for medical and scientific purposes while minimising misuse and dependence. The guidance, which includes a Country Assessment Checklist for operationalising its recommendations, can be used by governments and others to review policies and legislation.

Over the years, the WHO Access to Controlled Medications Programme experienced a tendency to focus on pain patients and even on cancer pain patients only. However, the WHO estimates that there are, in addition to the 5.5 million cancer pain patients untreated for pain every year, tens of millions other pain patients who are not treated for their moderate or severe pain. Moreover, it is estimated that 1 million HIV infections could be prevented every year if methadone and/or buprenorphine were available for the treatment of dependence and annually 75 000 cases of maternal death from post-partum haemorrhage could be prevented if ergometrine (which is also a precursor for LSD) or oxytocin (not under international control) were readily available (World Health Organization, [@r10]). Benzodiazepines, although they may be over-prescribed in some countries, may be insufficiently available in other countries. Causes of the unavailability of controlled medicines may be similar for all these classes of medicine and therefore it is important that any action taken to improve access to and the availability of controlled medicines aims at *all* of these medicines.

Prescription medicines {#s2}
======================

A new threat to patients' access to these medicines is the misuse of prescription medicines. Often little distinction is made between prescription and prescribed medicines, between medicines legally distributed through pharmacies and medicines sold illicitly through the internet, counterfeit medicines or medicines obtained from crime. Many research publications on this topic do not define their sample population well, but a review that did so demonstrated very low figures for misuse of (0.25%) and dependence on (0.05%) opioids prescribed for pain treatment (Noble *et al*, [@r3]).

Misuse of prescription medicines is a problem in some countries, but more detailed information on the source of the medicines and the mechanisms behind their diversion is urgently needed. This is crucial in order to avoid the implementation of ineffective measures that only deny patient access to these essential medicines.

Conclusion {#s3}
==========

Psychiatrists all around the world have various stakes in controlled medicines. They have an urgent need to be able to prescribe methadone or buprenorphine for the evidence-based treatment of dependence and to use benzodiazepines for various other mental disorders. In collaboration with organisations of other medical specialists, their national associations should advocate improved access to these medicines. Furthermore, they can play a role in monitoring misuse of and dependence on these medicines when prescribing them and in collecting information on the mechanisms behind the diversion and misuse of prescription medicines.

These associations can, together with those of other medical specialties and patients' organisations, assess the situation with regard to controlled medicines in their country by using the recent WHO policy guidelines and the checklist mentioned above. Together they can call on governments to implement policies and legislation aimed at solving any problems identified and can promote attitudes and practices among their members that will help to overcome such problems.
